Millennium Pharmaceuticals, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$39.1M
Doctors Paid
3,955
Transactions
13,443
2017 Total
$39.1M
Payment Breakdown by Category
Research$29.8M (76.3%)
Consulting$2.7M (7.0%)
Travel$689,204 (1.8%)
Food & Beverage$313,853 (0.8%)
Royalty/License$94,769 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $29.8M | 1,062 | 76.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4.3M | 1,095 | 11.0% |
| Consulting Fee | $2.7M | 586 | 7.0% |
| Grant | $809,552 | 31 | 2.1% |
| Travel and Lodging | $689,204 | 1,716 | 1.8% |
| Food and Beverage | $313,853 | 8,415 | 0.8% |
| Space rental or facility fees (teaching hospital only) | $169,620 | 91 | 0.4% |
| Charitable Contribution | $130,747 | 13 | 0.3% |
| Royalty or License | $94,769 | 5 | 0.2% |
| Education | $29,091 | 415 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $4,279 | 14 | 0.0% |
Payments by Type
Research
$29.8M
1,062 transactions
General
$9.3M
12,381 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Name of Study-Preclinical & Clinical Development of PS-341 (NSCD681239), A Protesome Inhibitor | $2.4M | 0 | 1 |
| Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma | $1.6M | 0 | 139 |
| A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma | $1.3M | 0 | 1 |
| A phase II study of the efficacy and safety of lenalidomide, subcutaneous bortezomib, and dexamethasone combination therapy for patients with newly diagnosed multiple myeloma | $1.2M | 0 | 6 |
| MD Anderson Cancer Center CCR | $1.0M | 0 | 1 |
| Phase 2 Study with Pevonedistat in combination with azacitidine in TP53 Mutant Untreated Acute Myeloid Leukemia ??? 60 years of age | $794,977 | 0 | 1 |
| IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma | $764,072 | 0 | 97 |
| Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis | $730,730 | 1 | 38 |
| Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer | $708,586 | 5 | 66 |
| A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG) | $660,861 | 0 | 16 |
| A Phase II, Multicenter, Randomized, Parallel Group Study to Compare Alisertib in Combination with Paclitaxel vs. Paclitaxel Alone in Patients with Metastatic or Locally Recurrent Breast Cancer | $589,394 | 0 | 1 |
| Study of Oral IXAZOMIB in Adult Patients With Relapsed and/or Refractory Multiple Myeloma | $554,704 | 0 | 7 |
| A Phase 1, Dose Escalation Study of MLN7243 in Adult Patients With Advanced Solid Tumors | $523,383 | 0 | 11 |
| Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma | $517,196 | 0 | 35 |
| Ixazomib for Treatment of Chronic Graft vs. Host Disease | $497,826 | 0 | 1 |
| Dose Finding Study of Vedolizumab for Graft-Versus-Host Disease (GvHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) | $474,394 | 0 | 5 |
| Study of MLN4924 Plus Azacitidine in Treatment-Na??ve Patients With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older | $471,752 | 0 | 7 |
| Prospective Observation of Cardiac Safety with Proteasome Inhibition (PROTECT) | $390,107 | 0 | 1 |
| A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors | $370,303 | 3 | 13 |
| A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma | $365,420 | 0 | 6 |
| A Phase I Two-Dimensional Dose-Finding Study of ixazomib in Combination with Gemcitabine and Doxorubicin, Followed by a Phase II Extension to Assess the Efficacy of this Combination in Metastatic, Surgically Unresectable Urothelial Cancer | $348,522 | 0 | 1 |
| A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer | $330,000 | 0 | 1 |
| A phase II study of the aurora A kinase inhibitor alisertib in combination with 7+3 induction chemotherapy in patients with high-risk acute myeloid leukemia | $293,823 | 0 | 1 |
| Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Patients With Advanced Solid Tumors | $281,336 | 0 | 6 |
| Safety Study of TAK-700 in Subjects With Prostate Cancer | $257,368 | 0 | 1 |
| An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn's Disease | $246,682 | 0 | 43 |
| Phase II study of Ixazomib, lenalidomide and dexamethasone in Smoldering Myeloma | $243,066 | 0 | 1 |
| MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma | $236,171 | 0 | 30 |
| AP24534-14-203(PH Phase 2) | $228,976 | 0 | 15 |
| Dose Escalation Study of MLN0128 in Subjects With Advanced Malignancies | $219,980 | 0 | 11 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2017 |
|---|---|---|---|---|
| Dr. Dennis Vargo, M.d, M.D | Internal Medicine | Boston, MA | $204,214 | $0 |
| Dr. Amitabha Mazumder, M.d, M.D | Specialist | Downey, CA | $164,604 | $0 |
| Robert Fram, M.d, M.D | Hematology & Oncology | Cambridge, MA | $159,285 | $0 |
| Hakan Kaya, M.d, M.D | Medical Oncology | Spokane, WA | $152,592 | $0 |
| Dr. Julia Laguette, M.d, M.D | Cytopathology | Chestnut Hill, MA | $129,621 | $0 |
| Dr. David Vesole, Md, MD | Hematology | Hackensack, NJ | $128,055 | $0 |
| Dr. Parameswaran Hari, Md, MD | Hematology & Oncology | Milwaukee, WI | $106,404 | $0 |
| Ehsan Malek, M.d, M.D | Medical Oncology | Buffalo, NY | $105,206 | $0 |
| Dr. Ling Chin, Md, Mph, MD, MPH | Public Health & General Preventive Medicine | Rockville, MD | $98,159 | $0 |
| Dr. James Mccloskey, M.d, M.D | Hematology | Hackensack, NJ | $90,592 | $0 |
| Alberto Chiappori, Md, MD | Internal Medicine | Tampa, FL | $79,667 | $0 |
| Imad Tabbara, M.d, M.D | Hematology & Oncology | Washington, DC | $77,741 | $0 |
| Dr. Suzanne Fanning, D.o, D.O | Hematology & Oncology | Greenville, SC | $70,008 | $0 |
| Dr. David Alpers, Md, MD | Gastroenterology | Saint Louis, MO | $64,424 | $0 |
| Dr. Elaine Peskind, Md, MD | Geriatric Psychiatry | Seattle, WA | $61,507 | $0 |
| Dr. Michael Castine, Md, MD | Medical Oncology | Baton Rouge, LA | $59,557 | $0 |
| Ilan Shapira, Md, MD | Internal Medicine | New York, NY | $52,819 | $0 |
| Perry Cook, M.d, M.D | Hematology & Oncology | Brooklyn, NY | $49,775 | $0 |
| Dr. David Siegel, Md, MD | Hematology | Hackensack, NJ | $46,529 | $0 |
| Dr. Joshua Richter, M.d, M.D | Medical Oncology | New York, NY | $46,092 | $0 |
| Dr. James Berenson, M.d, M.D | Specialist | West Hollywood, CA | $45,996 | $0 |
| Dr. Moshe Levy, Md, MD | Medical Oncology | Dallas, TX | $44,618 | $0 |
| Kelly Mccaul, M.d, M.D | Hematology & Oncology | Sioux Falls, SD | $44,416 | $0 |
| William Bensinger, Md, MD | Internal Medicine | Lakewood, WA | $43,358 | $0 |
| David Dingli, M.d, M.D | Hematology & Oncology | Rochester, MN | $43,060 | $0 |
About Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. has made $39.1M in payments to 3,955 healthcare providers, recorded across 13,443 transactions in the CMS Open Payments database. In 2017, the company paid $39.1M. The top product by payment volume is NINLARO ($10.8M).
Payments were distributed across 87 medical specialties. The top specialty by payment amount is Hematology & Oncology ($2.8M to 1,784 doctors).
Payment categories include: Food & Beverage ($313,853), Consulting ($2.7M), Research ($29.8M), Travel & Lodging ($689,204), Royalties ($94,769).
Millennium Pharmaceuticals, Inc. is associated with 1 products in the CMS Open Payments database.